证券代码：600976 证券简称：健民集团 公告编号：2024-036 健民药业集团股份有限公司 关于修订《公司章程》部分条款的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 特此公告。 健民药业集团股份有限公司 董事会 二○二四年十一月二十七日 健民药业集团股份有限公司（以下简称"公司"）2024 年 11 月 26 日召开 的第十届董事会第二十九次会议，会议以"8 票同意、1 票弃权"的表决结果审 议通过"关于修订《公司章程》部分条款的议案"，并将上述议案提交股东大会 审议。 根据《公司法》第十条第一款规定"公司的法定代表人按照公司章程的规定， 由代表公司执行公司事务的董事或者经理担任。"，公司拟修改《公司章程》第 八条相关内容，具体如下： | 修订前 | 修订后 | | --- | --- | | 第八条 董事长为公司的法定代表人。 | 第八条 董事长或者总经理（总裁）为公司的 | | | 法定代表人。 | 除上述修订内容外，其余条款不做修订，公司本次《公司章程》部分条款的 修订尚需股东大会批准。 附件：《健 ...

证券代码：600976 证券简称：健民集团 公告编号：2024-037 健民药业集团股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 健民药业集团股份有限公司（以下简称"公司"）依据中华人民共和国财政部 （以下简称"财政部"）发布的相关企业会计准则解释及规定要求变更会计政策。 具体如下： 一、会计政策变更概述 （一）会计政策变更原因 2024 年 11 月 26 日，公司第十届董事会第十三次审计委员会会议全票审议通过 《关于会计政策变更的议案》，同意公司根据财政部相关规定及要求执行新会计政 策，并将本议案提交董事会审议。 2023年8月1日，财政部发布《企业数据资源相关会计处理暂行规定》（财会{2023〕 11号）（以下简称"《数据资源暂行规定》"），该规定自2024年1月1日起执行。 2023年10月25日，财政部发布《关于印发<企业会计准则解释第17号>的通知》 （财会〔2023〕21号）（以下简称"《准则解释第17号》"），规定"关于流动负 债与非流动负债的划分"、"关于供应商融 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600976 证券简称：健民集团 公告编号：2024-038 健民药业集团股份有限公司 关于召开 2024 年第二次临时股东大会的通知 重要内容提示： 股东大会召开日期：2024年12月12日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 一、 召开会议的基本情况 (一) 股东大会类型和届次:2024 年第二次临时股东大会 (二) 股东大会召集人：董事会 2024 年 11 月 26 日召开的公司第十届董事会第二十九次会议以"8 票同意、 1 票弃权"的表决结果审议通过《关于召开 2024 年第二次临时股东大会的议案》， 公司 2024 年第二次临时股东大会的召集、召开符合国家现行法律、法规及《公 司章程》的有关规定。 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相 结合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2024 年 12 月 12 日 14 点 00 分 召开地点：湖北省武汉市汉阳区鹦鹉大道 ...

证券代码：600976 证券简称：健民集团 公告编号：2024-035 同意：8 票 弃权：1 票 反对：0 票 何勤先生因身体健康原因未能出席本次会议，亦未进行委托，视为放弃权利。 选举许良先生为公司第十届董事会副董事长，根据《公司章程》的有关规定，董事 长不能履行职务或者不履行职务的，由副董事长履行职务。 许良先生简历如下： 许良，男,1973 年 7 月出生,澳大利亚国立南澳大学 MBA/EMBA,曾任深圳华润三九医 药贸易有限公司财务部核算财务经理兼资金经理、财务部部长,华润三九现代中药股份 有限公司财务总监,华润三九医药股份有限公司财务管理中心助理总经理,浙江省医药 工业有限公司财务总监,华立医药集团有限公司财务总监，华立集团股份有限公司财务 营运副总监，杭州华方医院有限公司董事，浙江华方医护有限公司董事。现任华立集团 股份有限公司财务总监，华立医药集团有限公司董事长，浙江华立海外实业发展有限公 司董事，健民药业集团股份有限公司董事，未持有健民集团股份。 健民药业集团股份有限公司 第十届董事会第二十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 20% relative to the market benchmark within the next six months [13]. Core Views - The company experienced revenue and profit declines in Q3 2024, with total revenue of 8.7 billion and a net profit of 0.8 billion, representing a 9% and 50% year-on-year decrease, respectively [1]. - The company is focusing on key product lines and has seen stable profit contributions from its subsidiary, Dapeng, which reported a profit of 0.6 billion in Q3 2024, up 12% year-on-year [1]. - The report highlights the strong demand for cultured cow bile, with the company being the exclusive producer, leading to consistent profit growth from this segment [1]. Financial Performance Summary - For the first three quarters of 2024, the company achieved revenue of 28.8 billion, down 8% year-on-year, and a net profit of 3.2 billion, down 23% year-on-year [1]. - The revenue forecast for 2024 has been revised down to 40.8 billion, with expected growth rates of -3% for 2024, followed by 10% for 2025 and 2026 [1]. - The net profit forecast for 2024 has been adjusted to 4.5 billion, with a projected decline of 14%, followed by increases of 27% and 24% in 2025 and 2026, respectively [1]. Business Segment Analysis - The OTC product line is focused on pure sales, effectively reducing channel inventory, with notable growth in market share for key products like Longmu Zhuanggu Granules and Bian Tong Capsules [1]. - The Rx product line emphasizes academic leadership and the enhancement of the agent team, with new product launches such as Qian Rui Wei Shu Capsules performing well in the market [1]. - The report notes that the company is actively preparing for new drug market access, with a completed reserve of agent customers for pediatric products [1].

Financial Performance - The company's operating revenue for Q3 2024 was ¥871,720,993, a decrease of 8.83% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was ¥82,258,112, down 49.46% year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥76,514,611, a decrease of 36.37% compared to the same period last year[4]. - The basic earnings per share for Q3 2024 was ¥0.54, reflecting a decline of 49.53% year-on-year[4]. - The weighted average return on equity for Q3 2024 was 3.50%, down 3.89 percentage points from the previous year[4]. - Total operating revenue for the first three quarters of 2024 was CNY 2,881,317,090.47, a decrease of 7.57% compared to CNY 3,117,619,192.23 in the same period of 2023[17]. - Net profit for the third quarter of 2024 was CNY 324,587,553.14, a decline of 22.08% from CNY 416,690,389.61 in the same quarter of 2023[19]. - Earnings per share for the third quarter of 2024 were CNY 2.10, compared to CNY 2.72 in the same period of 2023, indicating a decrease in profitability per share[21]. Assets and Liabilities - Total assets at the end of Q3 2024 amounted to ¥4,205,324,282, an increase of 0.90% from the end of the previous year[4]. - The equity attributable to shareholders at the end of Q3 2024 was ¥2,393,859,370, up 6.50% from the end of the previous year[4]. - The company's total liabilities as of the end of the third quarter of 2024 were CNY 1,799,048,552.39, a slight decrease from CNY 1,911,466,639.41 in the previous year[19]. - Total current liabilities decreased to RMB 1,718,469,147.38 from RMB 1,856,942,135.52, a reduction of about 7.4%[15]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥105,781,248, a decrease of 36.99% year-on-year[4]. - In the first three quarters of 2024, the cash inflow from operating activities was CNY 3,240,143,517.02, a slight increase from CNY 3,191,838,251.25 in the same period of 2023, representing a growth of approximately 1.5%[22]. - The net cash flow from operating activities for the first three quarters of 2024 was CNY 105,781,248.03, down from CNY 167,889,871.63 in 2023, indicating a decline of about 37.0%[22]. - Cash inflow from financing activities totaled CNY 194,147,900.71 in the first three quarters of 2024, up from CNY 155,402,505.49 in 2023, marking an increase of about 24.9%[23]. - The net cash flow from financing activities was CNY -97,605,918.79 in 2024, worsening from CNY -48,111,642.62 in 2023, indicating a decline of approximately 102.1%[23]. Operational Efficiency - The company experienced a decline in pharmaceutical sales due to changes in marketing strategies and increased procurement costs[9]. - Total operating costs for the third quarter of 2024 were CNY 2,770,674,778.90, down from CNY 2,880,978,852.52 in the previous year, reflecting a cost reduction strategy[19]. - The company reported a decrease in sales expenses to CNY 918,789,285.72 from CNY 1,019,762,565.19, indicating improved cost management in sales operations[19]. Investments and Research - Research and development expenses for the first three quarters of 2024 were CNY 60,448,309.19, an increase from CNY 52,007,975.33 in the same period of 2023, reflecting a commitment to innovation[19]. - The company reported a significant increase in long-term equity investments to RMB 475,702,517.81 from RMB 410,014,958.81, a rise of about 16.0%[14]. Other Financial Metrics - The company reported non-recurring gains of ¥5,743,501 for the current period, with a total of ¥50,803,367 for the year-to-date[5]. - Deferred income increased significantly to CNY 46,989,387.01 from CNY 18,610,226.96, suggesting potential future revenue recognition[19]. - The ending balance of cash and cash equivalents as of the end of the third quarter of 2024 was CNY 180,774,348.01, compared to CNY 110,315,766.78 at the end of the same period in 2023, showing an increase of about 63.7%[23]. - The company has not disclosed any new product developments or market expansion strategies in this report[12].

关于推举董事代行董事长职务的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：600976 证券简称：健民集团 公告编号：2024-034 健民药业集团股份有限公司 健民药业集团股份有限公司董事长何勤先生近日因个人身体健康原因暂无法履行 董事长职务，根据《公司法》《公司章程》的有关规定，公司董事长不能履行职务或 者不履行职务的，由半数以上董事共同推举一名董事履行职务。 公司董事会根据《公司法》《公司章程》的有关规定，经董事共同推举，在何勤 先生不能履行职务期间由汪思洋先生代为履行第十届董事会董事长、战略发展与风险 控制委员会主任委员及公司法定代表人职责。 特此公告。 健民药业集团股份有限公司 二○二四年十月十八日 董事会 ...

证券代码：600976 证券简称：健民集团 公告编号：2024-033 健民药业集团股份有限公司 健民药业集团股份有限公司（以下简称"公司"）将于 2024 年 10 月 19 日发 布公司《2024 年第三季度报告》，为便于广大投资者更全面深入地了解公司 2024 年第三季度经营成果、财务状况，公司计划于 2024 年 10 月 21 日下午 13:00- 14:00 举行 2024 年第三季度业绩说明会，就投资者普遍关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2024 年第三季度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2024 年 10 月 21 日(星期一)下午 13:00-14:00 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2024 年 10 月 21 日(星期一 ...

Sales Performance - The pharmaceutical industrial sector experienced a decline in sales output compared to the same period last year due to a shift in assessment models from dispatch assessment to pure sales assessment [1] - OTC product line sales increased by 57% compared to the same period last year, with significant marketing efforts for products like Bian Tong capsules [1] - The sales output of Bian Tong capsules has shown a positive growth trend, supported by strategic partnerships with key chain pharmacies [2] Product Development - The prescription drug product line maintained a positive development trend, with slight sales increases for products like Bian Tong capsules and Xiao Er Bao Tai Kang granules [2] - The company has over 40 pediatric products, including the newly approved pediatric innovative drug, Xiao Er Zi Bei Xuan Fei syrup [2] - The company is focusing on the development of pediatric drugs, with more than half of the 25 new drug projects currently in research being pediatric products [2] Marketing Strategy - The company will continue to invest in advertising while maintaining a strategic approach to advertising scale and market targeting [2] - The dual-brand strategy around "Long Mu" and "Jian Min" will be emphasized to enhance brand strength and product sales [2] Future Development Plans - The company aims to refine marketing management and enhance digital marketing capabilities, focusing on high-quality health products and services [3] - There is a commitment to continue the development of innovative traditional Chinese medicine and pediatric drugs, with plans to explore mergers and acquisitions for product enhancement [3] - The company will accelerate production line upgrades and invest in smart manufacturing to strengthen sustainable development capabilities [3]

法律意见书 二○二四年九月三十日 湖北得伟君尚律师事务所 地址：武汉市江汉区建设大道 588 号卓尔国际大厦 20 楼、21 楼 电话：（86 27 8562 0999） 电子邮箱：dewell@ dewellcn.com 湖北得伟君尚律师事务所 关于健民药业集团股份有限公司 湖北得伟君尚律师事务所 关于健民药业集团股份有限公司 2024 年第一次临时股东大会的 2024 年第一次临时股东大会的法律意见书 致：健民药业集团股份有限公司 湖北得伟君尚律师事务所（以下简称本所）接受健民药业集团股份有限公司 （以下简称公司）的委托，指派律师出席公司 2024 年第一次临时股东大会，对公司 本次会议进行见证并出具法律意见书。 本所律师依据《公司法》《上市公司股东大会规则》《上海证券交易所上市公 司股东大会网络投票实施细则》(以下简称《网络投票细则》)及《公司章程》的规 定，对公司本次会议的召集与召开程序、召集人及出席会议人员的资格、表决程序 及表决结果的合法有效性发表法律意见。 本所律师根据《证券法》《律师事务所从事证券法律业务管理办法》和《律师 事务所证券法律业务执业规则（试行）》等规定的要求，严格履行法定职责，遵 ...